LCLenny Coppens

Lenny Coppens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lenny Coppens has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal immune profiling of Long COVID phenotypes reveals a shared persistent IL-17F-centered immune signature

    by Samir Kumar-Singh, An Hotterbeekx, Carolina Alvarez-Garavito, Lorenzo Canziani, Samuel Lebourgeois, Lenny Coppens, Elisa Gentilotti, Roy Gusinow, Aline-Marie Florence, Matilda Berkell, et al.

    The longitudinal immunological mechanisms driving the heterogeneous clinical phenotypes of Long COVID (LC) remain poorly understood. Here, we quantified 54 circulating immune biomarkers in 355 individuals followed for up to 24 months post-infection. Using joint factor analysis and Bayesian structural equation modelling, we demonstrate that despite clinical heterogeneity, the respiratory, chronic pain, and chronic fatigue-like LC phenotypes share a convergent immune signature. This signature is characterized by persistent upregulation of the Th17-associated cytokine IL-17F from 3 to 12 months. Early recovery phases were marked by down-regulated angiogenic factors, which later transitioned to sustained elevation of VEGF-C, fractalkine, eotaxin, and CTACK, indicating dysregulated vascular repair. While the neurosensorial phenotype lacked systemic immune perturbations, the chronic fatigue-like phenotype demonstrated a distinct, prolonged trajectory of active immune dysregulation driven by self-sustaining tissue remodelling rather than generalized hyperinflammation. These findings provide a longitudinal framework for understanding LC pathogenesis, identifying maladaptive immune-remodelling pathways as potential therapeutic targets in post-acute infection syndromes.

  • Open Access

    Comparative characterization of OncoPro™ and Wnt-Based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids

    by Sofie Seghers, Maxim Le Compte, Felicia Rodrigues Fortes, Jana Baroen, Jasper Ott, Geert Roeyen, Vera Hartman, Samir Kumar-Singh, Lenny Coppens, Michiel de Maat, et al.

    Background: Patient-derived tumor organoids (PDTOs) are strongly influenced by culture medium. We compared OncoPro™ (OP) Tumoroid Culture medium with conventional Wnt/R-spondin/noggin (Wnt) medium. This recently developed OP medium offers a standardized, serum-free alternative to Wnt-based formulations. Methods: We compared OP and Wnt media across 36 PDTO lines from various malignancies (colorectal, pancreatic, breast, lung, gastric, gastroesophageal junction, biliary head- and neck and uknown primary), assessing establishment success. Selected PDTO models were subjected to downstream characterization, including morphological assessment and bulk transcriptomic profiling with comparison to public single-cell RNA sequencing reference datasets (n=11), whole-exome sequencing (WES) (n=9), and pharmacological response profiling to a 33-drug panel (n=3). Results: Adaptation from Wnt medium to OP succeeded in 83.3% (15/18), whereas de novo establishment favored Wnt (33.3% vs 11.1%). Key oncogenic driver alterations were retained across matched organoid cultures, supporting preservation of tumor-relevant genomic features. Transcriptomic profiling confirmed preserved tumor-identity across media, while revealing different epithelial state programs: Wnt upregulated proliferation/stemness-associated genes (e.g. LGR5) and OP enriched adhesion-associated genes and inflammatory/TGF-β programs. In scRNA databases OP signatures preferentially mapped to malignant epithelial compartments in pancreatic cancer, whereas Wnt signatures were linked to non-malignant epithelium. Similarly, in colon cancer OP signature mapped predominantly to the malignant epithelial compartments. Drug (n=33) screening in pancreatic- and colorectal cancer PDTOs (n=3) demonstrated consistent medium-dependent shifts: Wnt-grown PDTOs were globally more sensitive in the screened subset, particularly to MAPK-axis inhibitors and apoptosis-sensitizers, while OP-grown PDTOs exhibited relative resistance. Conclusions: Culture medium composition is a key determinant of PDTO phenotype, transcriptome and drug sensitivity. Wnt medium was associated with drug-sensitive states, whereas OP medium was associated with adhesion- and inflammatory-related programs, relative resistance in the screened subset of 33 drugs and closer alignment with malignant epithelial programs in the analyzed pancreatic / colorectal cancer single-cell atlases.

  • Open Access

    Persistent Spike antigenemia is not associated with Post-COVID condition

    by Lenny Coppens, Anna Gorska, An Hotterbeekx, Lorenzo Maria Canziani, Valentin Octavian Mateescu, Elisa Gentilotti, Daniel Pirici, Matilda Berkell, Orchestra Biomarker Study Group, Surbhi Malhotra, et al.

    A bstract: Objectives: Spike antigenemia has been proposed as one of the potential mechanisms underlying post-COVID condition (PCC). Several studies addressing Spike antigenemia have measured both free and antibody-bound Spike employing 10 mM DTT to dissociate Spike–IgG complexes. Methods: Within the ORCHESTRA project, we analysed Spike and Nucleocapsid proteins in 188 participants, comprising PCC patients (n=112), non-PCC individuals (n=58) and pre-pandemic controls (n=18). For the post-pandemic cohort, 546 samples were studied from acute infection (n=99), and at 3, 6, 12, and 18 months follow-up (n=547). Impact of 10 mM DTT treatment on Spike detectability was evaluated. Correlations between Spike and proinflammatory markers were examined in both PCC and non-PCC groups. Results: DTT treatment of recombinant Spike reduced its detectability in a dose-dependent manner, with a 91.3% reduction observed at 10 mM concentration (p<0.001). In plasma, DTT treatment increased detection signals in acute COVID-19 and PCC patients (n=13) by 2.6-fold, except in an acutely infected individual with exceptionally high acute Spike levels (p<0.001). Notably, pre-pandemic plasma (n=18) also exhibited a fourfold increase in measurable signal following DTT exposure (p<0.001). Analysis of free Spike and Nucleocapsid revealed that Nucleocapsid was detectable in nearly all acute cases (n=98/99), whereas Spike was observed less frequently (15/99). Neither Spike nor Nucleocapsid antigenemia differed between PCC and controls, and no association was measured between Spike levels and PCC. Interestingly, Spike levels at 3 and 6 months correlated with inflammatory cytokines IL-6, IL-2, and IL-1β, with stronger associations observed within the PCC cohort (all p<0.05). Conclusions: Our findings indicate that DTT treatment induces Spike denaturation and artefactual neoepitope generation rather than genuine release of immune-complexed antigen. Furthermore, we demonstrate that PCC pathogenesis is less consistent with persistent Spike antigenemia. Together, these results call for harmonized biomarker methodologies for Spike antigenemia and more in-depth mechanistic studies of PCC.